Test Summary

Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR blocking autoantibodies prevent inter-action of binding antibodies with the AChR. Fewer than 1% of patients have blocking antibodies without binding antibodies. Blocking antibodies are present in about 50% of patients with MG, but rare in other conditions. Therefore, blocking antibodies have utility in ruling out a possible false positive binding assay and detecting the rare patient without AChR binding antibodies.

Aliases

Specimen Collection

Special Instructions

Preferred Specimen

Minimum Volume

Instructions

Patient Preparation

Storage

Transport Temperature

Specimen Stability

Limitations

Other Acceptable Specimens

Unacceptable Specimens

Order Code

EPIC (Premier) Code

Includes

CPT Code

Billing Code

CPT Statement

Methodology

FDA Status

Physician Attestation of Informed Consent

Testing Laboratory

Reference Range

Setup Schedule / Expected Turnaround Time